AlphaQuest LLC Acquires 2,705 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

AlphaQuest LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 171.0% during the fourth quarter, HoldingsChannel reports. The fund owned 4,287 shares of the biopharmaceutical company’s stock after purchasing an additional 2,705 shares during the quarter. AlphaQuest LLC’s holdings in Celldex Therapeutics were worth $108,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its holdings in Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Bellevue Group AG grew its holdings in Celldex Therapeutics by 3.4% during the 3rd quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after acquiring an additional 100,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Celldex Therapeutics by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock valued at $52,372,000 after purchasing an additional 6,557 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after purchasing an additional 321,325 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Celldex Therapeutics by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company’s stock valued at $13,755,000 after purchasing an additional 5,474 shares during the last quarter.

Celldex Therapeutics Trading Down 2.3 %

CLDX opened at $19.89 on Wednesday. The company’s fifty day moving average price is $22.58 and its two-hundred day moving average price is $27.50. Celldex Therapeutics, Inc. has a 1-year low of $18.61 and a 1-year high of $47.00. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -7.74 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. As a group, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. The Goldman Sachs Group cut their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, UBS Group assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $55.38.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.